Many of us skim the surface when looking at Kevetrin but you really dig right down into the meat of the subject. Great read!
Looking at the CTIX pipeline of products, it seems that most of the small molecule drugs being developed work well thru many different avenues. You so aptly just described how Kevetrin could work in any number of different ways to help conquer cancer. I am sure Prurisol has been mentioned as being another extremely strong combinatory candidate for working with other drugs against all autoimmune problems and then Brilacidin is being tested for 2 different applications; skin infections and mucositis. Is this a coincidence or do small molecule drugs in general have a greater ability to work in a number of different ways so as to be multi-dimensional whereas most prior drugs were one dimensional? Could we be looking at our pipeline as a source of "super" drugs in regard to this multi dimensional ability? Just a thought to chew on.
I know big pharmas probably have tremendous research depts, but I don't see how anybody could look at CTIX and their pipeline of products and expertise in the development of small molecule drugs and not recognize that this is a MAJOR force to be reckoned with in the very near future in becoming THE acknowledged company at the forefront of small molecule drug development. Disclaimer: I am highly biased towards CTIX and proud of it.
When the time comes for buyout/alliance/etc if Leo and Dr M don't want to make CTIX a stand alone pharma, I think a big pharma would be crazy not trying to corral the whole ball of wax instead of just partnering a drug or two. It is apparent even to my layman eyes that this company and their pipeline could be the basis for many, many years of blockbuster new products for whatever big pharma that wins the golden ring in acquiring CTIX.
Market Data 
Markets 
AI
